Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Open access

Abstract

Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression of immune cell function by cytostatic drugs may limit therapeutic efficacy. Here we show that targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) does not impair dendritic cell-mediated T cell priming and activation. Accordingly, combining MEK inhibitors (MEKi) with agonist antibodies (Abs) targeting the immunostimulatory CD40 receptor results in potent synergistic antitumor efficacy. Detailed analysis of the mechanism of action of MEKi shows that this drug exerts multiple pro-immunogenic effects, including the suppression of M2-type macrophages, myeloid derived suppressor cells and T-regulatory cells. The combination of MEK inhibition with agonist anti-CD40 Ab is therefore a promising therapeutic concept, especially for the treatment of mutant Kras-driven tumors such as pancreatic ductal adenocarcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-15979-2

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 In vitro potency of MEK and PI3K inhibitors against syngeneic tumor cell lines. ATP-based assessment of tumor cell viability in presence of indicated concentrations of small molecule inhibitors. Relative cell viability normalized to medium control. Inhibitory concentration (IC) 50 values calculated with 4-parameter logistic curve fit with bottom constraint >0. Mean ± s.e.m, n = 3. a Representative dose–response curves of murine tumor cell lines. b Mean IC50 values for indicated murine tumor cell lines of three independent experiments. Each experiment comprises three biological replicates. Shading indicates level of inhibitor potency (red: < 200 nM = sensitive; orange: 200–1000 nM = moderate; light yellow: > 1000 nM = not sensitive). c Western Blot analyses of indicated murine tumor cell lines treated with 0.5 µM GDC-0623 for 1 h. Representative data shown from two technical replicates. d, e Ki67/PI-based cell cycle analyses of tumor cells treated with 1 µM GDC-0623 and respective quantification. Mean ± s.e.m, n = 3. Unpaired student t test (medium vs. GDC-0623 for each cell cycle phase; FDR (Q = 1%), two-stage step-up method of Benjamini, Krieger and Yuketieli). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; *** p ≤ 0.001; ****p ≤ 0.0001).
Fig. 1 In vitro potency of MEK and PI3K inhibitors against syngeneic tumor cell lines. ATP-based assessment of tumor cell viability in presence of indicated concentrations of small molecule inhibitors. Relative cell viability normalized to medium control. Inhibitory concentration (IC) 50 values calculated with 4-parameter logistic curve fit with bottom constraint >0. Mean ± s.e.m, n = 3. a Representative dose–response curves of murine tumor cell lines. b Mean IC50 values for indicated murine tumor cell lines of three independent experiments. Each experiment comprises three biological replicates. Shading indicates level of inhibitor potency (red: < 200 nM = sensitive; orange: 200–1000 nM = moderate; light yellow: > 1000 nM = not sensitive). c Western Blot analyses of indicated murine tumor cell lines treated with 0.5 µM GDC-0623 for 1 h. Representative data shown from two technical replicates. d, e Ki67/PI-based cell cycle analyses of tumor cells treated with 1 µM GDC-0623 and respective quantification. Mean ± s.e.m, n = 3. Unpaired student t test (medium vs. GDC-0623 for each cell cycle phase; FDR (Q = 1%), two-stage step-up method of Benjamini, Krieger and Yuketieli). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; *** p ≤ 0.001; ****p ≤ 0.0001).CC BY · PubMed Central
Fig. 2 Chemotherapeutic agents, but not MEK inhibitors, impair T cell proliferation and activation in vivo. a C57BL/6-Ly5.1 (CD45.1+) mice infused with CFSE-labeled OT-I T cells (CD45.2+) were treated for 6 days with the indicated doses of MEK inhibitor GDC-0623 or vehicle. Mice were immunized with OVA protein admixed with anti-CD40 Ab. After 3 days, splenocytes were analyzed. Upper row: dot plots of gated OT-I T cells. Lower row: CFSE dilution of gated OT-I T cells; differentially colored histograms represent data from individual mice. Bar charts to the right: cumulative data from six experiments (total mice: vehicle n = 23, GDC-0623 (10 mg kg−1) n = 19, GDC-0623 (30 mg kg−1) n = 21), showing quantification of OT-I T cell numbers and divided fraction. One-way ANOVA with post hoc Tukey’s test. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). b Intracellular IFNγ levels of OT-I T cells after ex vivo restimulation with SIINFEKL peptide. Bar charts to the right: cumulative data of four experiments (total n ≥ 12 mice per group). c CD45.1+ mice infused with naive CD45.2+ OT-I T cells were immunized with OVA protein admixed with anti-CD40 Ab. Three days later, mice were infused with CFSE-labeled peptide pulsed target cells (CD45.2+ splenocytes pulsed with 10 µg ml−1 SIINFEKL; 0.3 µm CFSE) admixed with control cells (CD45.2+ splenocytes pulsed with 10 µg ml−1 P53 control peptide AIYKKSQHM; 5 µm CFSE); spleens were analyzed for target cell killing after 24 h. GDC-0623 was administered at indicated doses for 3 days after immunization. Bar charts to the right: cumulative data of two experiments (vehicle n = 8, GDC-0623 (10 mg kg−1) n = 6, GDC-0623 (30 mg kg−1) n = 6) with specific killing normalized to the T cell only group. d As described in a, mice were treated on days 0 and 3 with indicated doses of temozolomide (TEM), gemcitabine (GEM), or vehicle. Upper row: dot plots of gated OT-I T cells. Lower row: CFSE dilution of gated OT-I T cells. Bar charts to the right: quantification of OT-I T cell numbers and divided fraction (three mice/group).
Fig. 2 Chemotherapeutic agents, but not MEK inhibitors, impair T cell proliferation and activation in vivo. a C57BL/6-Ly5.1 (CD45.1+) mice infused with CFSE-labeled OT-I T cells (CD45.2+) were treated for 6 days with the indicated doses of MEK inhibitor GDC-0623 or vehicle. Mice were immunized with OVA protein admixed with anti-CD40 Ab. After 3 days, splenocytes were analyzed. Upper row: dot plots of gated OT-I T cells. Lower row: CFSE dilution of gated OT-I T cells; differentially colored histograms represent data from individual mice. Bar charts to the right: cumulative data from six experiments (total mice: vehicle n = 23, GDC-0623 (10 mg kg−1) n = 19, GDC-0623 (30 mg kg−1) n = 21), showing quantification of OT-I T cell numbers and divided fraction. One-way ANOVA with post hoc Tukey’s test. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). b Intracellular IFNγ levels of OT-I T cells after ex vivo restimulation with SIINFEKL peptide. Bar charts to the right: cumulative data of four experiments (total n ≥ 12 mice per group). c CD45.1+ mice infused with naive CD45.2+ OT-I T cells were immunized with OVA protein admixed with anti-CD40 Ab. Three days later, mice were infused with CFSE-labeled peptide pulsed target cells (CD45.2+ splenocytes pulsed with 10 µg ml−1 SIINFEKL; 0.3 µm CFSE) admixed with control cells (CD45.2+ splenocytes pulsed with 10 µg ml−1 P53 control peptide AIYKKSQHM; 5 µm CFSE); spleens were analyzed for target cell killing after 24 h. GDC-0623 was administered at indicated doses for 3 days after immunization. Bar charts to the right: cumulative data of two experiments (vehicle n = 8, GDC-0623 (10 mg kg−1) n = 6, GDC-0623 (30 mg kg−1) n = 6) with specific killing normalized to the T cell only group. d As described in a, mice were treated on days 0 and 3 with indicated doses of temozolomide (TEM), gemcitabine (GEM), or vehicle. Upper row: dot plots of gated OT-I T cells. Lower row: CFSE dilution of gated OT-I T cells. Bar charts to the right: quantification of OT-I T cell numbers and divided fraction (three mice/group).CC BY · PubMed Central
Fig. 3 Combination of MEK inhibition with agonist anti-CD40 Ab mediates control of established tumors. a–c Outgrowth of B16-OVA, MC-38, and PDA30364 tumors upon treatment with MEKi GDC-0623 and/or anti-CD40 Ab. Mice were treated daily with 30 mg kg−1 GDC-0623 or vehicle for ~2 weeks (gray rectangle). Anti-CD40 or control Ab were administered on treatment days 3, 5, 7 as well as 1 day prior to biomarker analyses (green arrows). Each group consisted of at least six mice (nB16-OVA = 10, nMC38 = 10, nPDA30364 = 10). Four mice per group were killed at end of treatment for biomarker analyses. Two-way ANOVA with post hoc Dunnett’s test; treatment groups vs. control. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). d Cumulative data of several experiments with the PDA30364 tumor model. e PDA30364 tumor growth in mice treated with monotherapies (anti-CD40 Ab, anti-PD-1 Ab, or GDC-0623) and combination therapies (anti-CD40 Ab + GDC-0623 and anti-PD-1 Ab+GDC-0623). Mice were treated daily with 30 mg kg−1 GDC-0623 or vehicle for ~5 weeks. Anti-CD40, anti-PD-1, and control Ab were administered twice weekly (arrows). Each group consisted of at least nine mice (nControl = 9, nCD40 = 9, nGDC-0623 = 12, nCD40+GDC-0623 = 10, nPD-1 = 10, nPD1-GDC-0623 = 11). Four mice per group were killed 2 weeks after treatment start for biomarker analyses. f Impact of T cell depletion on efficacy of GDC-0623 and/or anti-CD40 Ab treatment against PDA30364 tumors. Where indicated, groups received depletory anti-CD4, anti-CD8 or anti-CD4+ anti-CD8 Abs twice per week. Each group consisted of at least five mice.
Fig. 3 Combination of MEK inhibition with agonist anti-CD40 Ab mediates control of established tumors. a–c Outgrowth of B16-OVA, MC-38, and PDA30364 tumors upon treatment with MEKi GDC-0623 and/or anti-CD40 Ab. Mice were treated daily with 30 mg kg−1 GDC-0623 or vehicle for ~2 weeks (gray rectangle). Anti-CD40 or control Ab were administered on treatment days 3, 5, 7 as well as 1 day prior to biomarker analyses (green arrows). Each group consisted of at least six mice (nB16-OVA = 10, nMC38 = 10, nPDA30364 = 10). Four mice per group were killed at end of treatment for biomarker analyses. Two-way ANOVA with post hoc Dunnett’s test; treatment groups vs. control. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). d Cumulative data of several experiments with the PDA30364 tumor model. e PDA30364 tumor growth in mice treated with monotherapies (anti-CD40 Ab, anti-PD-1 Ab, or GDC-0623) and combination therapies (anti-CD40 Ab + GDC-0623 and anti-PD-1 Ab+GDC-0623). Mice were treated daily with 30 mg kg−1 GDC-0623 or vehicle for ~5 weeks. Anti-CD40, anti-PD-1, and control Ab were administered twice weekly (arrows). Each group consisted of at least nine mice (nControl = 9, nCD40 = 9, nGDC-0623 = 12, nCD40+GDC-0623 = 10, nPD-1 = 10, nPD1-GDC-0623 = 11). Four mice per group were killed 2 weeks after treatment start for biomarker analyses. f Impact of T cell depletion on efficacy of GDC-0623 and/or anti-CD40 Ab treatment against PDA30364 tumors. Where indicated, groups received depletory anti-CD4, anti-CD8 or anti-CD4+ anti-CD8 Abs twice per week. Each group consisted of at least five mice.CC BY · PubMed Central
Fig. 4 MEKi/anti-CD40 Ab combination therapy increases CD8/Treg ratio and effector function of tumor-infiltrating T cells. a Flow cytometric analysis of the impact of MEKi GDC-0623 and/or anti-CD40 Ab treatment on the T cell infiltrate in B16-OVA, MC-38, and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. Representative dot plots are shown. Cells were pre-gated on living, CD45+, CD3+, Thy-1.2+ cells. b–d Quantitation of CD8+ T cell to CD4+ CD25+ Foxp3+ regulatory T cell ratio, regulatory T cell frequencies among CD4+ T cells, and CD8+ T cell frequencies among living cells. #Two animals without Tregs. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). Mean ± s.e.m, n = 4. e TILs isolated from PDA30364 tumors were restimulated ex vivo with PMA/Ionomycin in presence of GolgiPlug and stained for intracellular IFNγ and TNFα. Mean ± s.e.m., n = 4. One-way ANOVA with post hoc Tukey’s test. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).
Fig. 4 MEKi/anti-CD40 Ab combination therapy increases CD8/Treg ratio and effector function of tumor-infiltrating T cells. a Flow cytometric analysis of the impact of MEKi GDC-0623 and/or anti-CD40 Ab treatment on the T cell infiltrate in B16-OVA, MC-38, and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. Representative dot plots are shown. Cells were pre-gated on living, CD45+, CD3+, Thy-1.2+ cells. b–d Quantitation of CD8+ T cell to CD4+ CD25+ Foxp3+ regulatory T cell ratio, regulatory T cell frequencies among CD4+ T cells, and CD8+ T cell frequencies among living cells. #Two animals without Tregs. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). Mean ± s.e.m, n = 4. e TILs isolated from PDA30364 tumors were restimulated ex vivo with PMA/Ionomycin in presence of GolgiPlug and stained for intracellular IFNγ and TNFα. Mean ± s.e.m., n = 4. One-way ANOVA with post hoc Tukey’s test. Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).CC BY · PubMed Central
Fig. 5 MEKi suppress M2-like macrophages and MDSCs. a Flow cytometric analysis of the impact of MEKi GDC-0623 and/or anti-CD40 Ab treatment on the macrophage infiltrate in MC-38 and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3 b–c. Representative dot plots are shown. Cells were pre-gated on living CD45+, CD11b+, F4/80+ cells. One-way ANOVA with post hoc Dunnetts’s test (treatment groups vs. control). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). b Polarization of mouse bone marrow-derived macrophage cultures towards M1- or M2-like phenotype, as assessed by flow cytometry marker analysis. Mean ± s.e.m, n = 6. c Cell viability of polarized macrophages after 3-day treatment with GDC-0623. Left panel: representative dose–response curves. Relative IC50 values were calculated by four-parameter logistic curve fit with a bottom constraint > 0. Mean ± s.e.m, n = 3. Right panel: Ki67/PI-based cell cycle analyses of tumor cells treated with 1 µm GDC-0623 and respective quantification. Mean ± s.e.m, n = 3. Unpaired student t test (medium vs. GDC-0623 for each cell cycle phase; FDR (Q = 1%), two-stage step-up method of Benjamini, Krieger and Yuketieli). d Representative dot plots of myeloid cell populations in MC-38 and PDA30364 tumors. e Representative dot plots of 'Gr1+', Ly6C+Ly6G+, and Ly6C+ Ly6G− myeloid cell populations in PDA30364 tumors. Cells were pre-gated on living CD45+, CD11b+ cells; quantitation normalized to all living cells. Mean ± s.e.m, n = 4. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). F Cell viability of bone marrow-derived MDSC cultures after 3-day treatment with GDC-0623; assay performed as described above. Mean ± s.e.m, n = 3.
Fig. 5 MEKi suppress M2-like macrophages and MDSCs. a Flow cytometric analysis of the impact of MEKi GDC-0623 and/or anti-CD40 Ab treatment on the macrophage infiltrate in MC-38 and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3 b–c. Representative dot plots are shown. Cells were pre-gated on living CD45+, CD11b+, F4/80+ cells. One-way ANOVA with post hoc Dunnetts’s test (treatment groups vs. control). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). b Polarization of mouse bone marrow-derived macrophage cultures towards M1- or M2-like phenotype, as assessed by flow cytometry marker analysis. Mean ± s.e.m, n = 6. c Cell viability of polarized macrophages after 3-day treatment with GDC-0623. Left panel: representative dose–response curves. Relative IC50 values were calculated by four-parameter logistic curve fit with a bottom constraint > 0. Mean ± s.e.m, n = 3. Right panel: Ki67/PI-based cell cycle analyses of tumor cells treated with 1 µm GDC-0623 and respective quantification. Mean ± s.e.m, n = 3. Unpaired student t test (medium vs. GDC-0623 for each cell cycle phase; FDR (Q = 1%), two-stage step-up method of Benjamini, Krieger and Yuketieli). d Representative dot plots of myeloid cell populations in MC-38 and PDA30364 tumors. e Representative dot plots of 'Gr1+', Ly6C+Ly6G+, and Ly6C+ Ly6G− myeloid cell populations in PDA30364 tumors. Cells were pre-gated on living CD45+, CD11b+ cells; quantitation normalized to all living cells. Mean ± s.e.m, n = 4. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). F Cell viability of bone marrow-derived MDSC cultures after 3-day treatment with GDC-0623; assay performed as described above. Mean ± s.e.m, n = 3.CC BY · PubMed Central
Fig. 6 Gene signatures reflect drug mechanism of action, including pro-immunogenic action of MEKi in PDA3034 tumors. Whole-tumor transcriptome analysis of the impact of MEK inhibitor GDC-0623 and/or anti-CD40 Ab treatment on the T cell infiltrate in B16-OVA, MC-38, and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. a–e Genes signatures based on differentially regulated genes (two-component empirical Bayes test with p < 0.05 and Benjamini–Hochberg correction for multiple testing) between MEKi/CD40 Ab and untreated tumors followed subsequent IPA core analyses; log2 FC. a Top 10 canonical pathways based on p value with focus on downregulated genes. b Top 10 differentially regulated genes of indicated pathways. c Gene expression changes of PDA30364 cell cultures treated with 100 nm GDC-0623 or vehicle for 24 and 72 hours with focus on genes identified in b. d Top 10 canonical pathways based on p value with focus on upregulated genes. e Top 10 differentially regulated genes of indicated pathways. f T cell marker expression normalized to control group; log2 FC and flow cytometric analyses of tumor-infiltrating T cells isolated from PDA30364 tumors. Mean ± s.e.m., n = 4 mice per treatment group. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). g Top 3 IPA ‘cellular immune response’ pathways after differential gene expression analyses (as above) of PDA30364 cell cultures treated with 100 nm GDC-0623 or vehicle for 24 and 72 hours. h Expression changes of genes associated with antigen presentation between aforementioned PDA30364 cell cultures; log2 FC. I Flow cytometric analysis of MHC levels on PDA30364-OVA tumor cells treated with 10 ng ml−1 IFNγ and/or 100 nm GDC-0623. Upper panel MHC-I (H2-Kb), middle panel MHC-I-OVA (H2-Kb-OVA), lower panel MHC-II (I-A/I-E). Mean ± s.e.m, n = 3. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control).
Fig. 6 Gene signatures reflect drug mechanism of action, including pro-immunogenic action of MEKi in PDA3034 tumors. Whole-tumor transcriptome analysis of the impact of MEK inhibitor GDC-0623 and/or anti-CD40 Ab treatment on the T cell infiltrate in B16-OVA, MC-38, and PDA30364 tumors, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. a–e Genes signatures based on differentially regulated genes (two-component empirical Bayes test with p < 0.05 and Benjamini–Hochberg correction for multiple testing) between MEKi/CD40 Ab and untreated tumors followed subsequent IPA core analyses; log2 FC. a Top 10 canonical pathways based on p value with focus on downregulated genes. b Top 10 differentially regulated genes of indicated pathways. c Gene expression changes of PDA30364 cell cultures treated with 100 nm GDC-0623 or vehicle for 24 and 72 hours with focus on genes identified in b. d Top 10 canonical pathways based on p value with focus on upregulated genes. e Top 10 differentially regulated genes of indicated pathways. f T cell marker expression normalized to control group; log2 FC and flow cytometric analyses of tumor-infiltrating T cells isolated from PDA30364 tumors. Mean ± s.e.m., n = 4 mice per treatment group. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). g Top 3 IPA ‘cellular immune response’ pathways after differential gene expression analyses (as above) of PDA30364 cell cultures treated with 100 nm GDC-0623 or vehicle for 24 and 72 hours. h Expression changes of genes associated with antigen presentation between aforementioned PDA30364 cell cultures; log2 FC. I Flow cytometric analysis of MHC levels on PDA30364-OVA tumor cells treated with 10 ng ml−1 IFNγ and/or 100 nm GDC-0623. Upper panel MHC-I (H2-Kb), middle panel MHC-I-OVA (H2-Kb-OVA), lower panel MHC-II (I-A/I-E). Mean ± s.e.m, n = 3. One-way ANOVA with post hoc Dunnett’s test (treatment groups vs. control).CC BY · PubMed Central
Fig. 7 Gene signatures correlate with treatment efficacy and reveal drug mechanism of action. a Gene signatures for each individual treatment regimen manually composed on the basis of differentially expressed genes between control and indicated treatment group of the MEKi/CD40 Ab experiment, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. In GEM/CD40 Ab PDA30364 experiments, 120 mg kg−1 GEM was administered on treatment days 1, 5, and 12 and anti-CD40 Ab on days 3, 4, 6, and 14; mean ± s.e.m. Each treatment group consisted of at least seven animals. Four mice per treatment group were analyzed on day 22/23 after tumor inoculation. b Tumor growth of GEM/CD40 Ab or monotherapy groups. Mean±s.e.m. Two-way ANOVA with post hoc Fisher’s LSD test (treatment groups vs. control; day 25). c Waterfall plots of GEM/CD40 Ab and MEKi/anti-CD40 Ab on day 22 after tumor inoculation. Each bar represents one individual mouse. Some data as in Fig. 3c and 7b. d Treatment of PDA30364 tumor-bearing mice with 120 mg kg−1 GEM or nanoparticle albumin bound paclitaxel (nAbP). nAbP was administered on treatment day 1 and GEM was dosed on days 1, 5, and 12. Anti-CD40 Ab on days 3, 4, 6, and 14. Mean ± s.e.m. Four mice per treatment group were sacrificed on days 22/23 after tumor inoculation. Note, the control, anti-CD40 Ab, GEM, GEM/anti-CD40 Ab groups are the same as in b. Two-way ANOVA with post hoc Fisher’s LSD test (treatment groups vs. control; day 25). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).
Fig. 7 Gene signatures correlate with treatment efficacy and reveal drug mechanism of action. a Gene signatures for each individual treatment regimen manually composed on the basis of differentially expressed genes between control and indicated treatment group of the MEKi/CD40 Ab experiment, as performed on four mice per treatment group of the experiments shown in Fig. 3a–c. In GEM/CD40 Ab PDA30364 experiments, 120 mg kg−1 GEM was administered on treatment days 1, 5, and 12 and anti-CD40 Ab on days 3, 4, 6, and 14; mean ± s.e.m. Each treatment group consisted of at least seven animals. Four mice per treatment group were analyzed on day 22/23 after tumor inoculation. b Tumor growth of GEM/CD40 Ab or monotherapy groups. Mean±s.e.m. Two-way ANOVA with post hoc Fisher’s LSD test (treatment groups vs. control; day 25). c Waterfall plots of GEM/CD40 Ab and MEKi/anti-CD40 Ab on day 22 after tumor inoculation. Each bar represents one individual mouse. Some data as in Fig. 3c and 7b. d Treatment of PDA30364 tumor-bearing mice with 120 mg kg−1 GEM or nanoparticle albumin bound paclitaxel (nAbP). nAbP was administered on treatment day 1 and GEM was dosed on days 1, 5, and 12. Anti-CD40 Ab on days 3, 4, 6, and 14. Mean ± s.e.m. Four mice per treatment group were sacrificed on days 22/23 after tumor inoculation. Note, the control, anti-CD40 Ab, GEM, GEM/anti-CD40 Ab groups are the same as in b. Two-way ANOVA with post hoc Fisher’s LSD test (treatment groups vs. control; day 25). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001).CC BY · PubMed Central
Fig. 8 Graphical representation of MEKi/CD40 Ab antitumor mechanism. MEK inhibitors induce tumor-intrinsic interferon response, enhance MHC-restricted antigen presentation and suppress M2 tumor-associated macrophages (M2 TAM), MDSCs and Tregs, but not M1 TAMs, DCs, and effector T cells. Agonist anti-CD40 provides co-stimulatory signal, increases antigen presentation, and stimulates CD4+ and CD8+ T cells. Complementary drug action of the MEKi/CD40 Ab combination exerts synergistic antitumor effects.
Fig. 8 Graphical representation of MEKi/CD40 Ab antitumor mechanism. MEK inhibitors induce tumor-intrinsic interferon response, enhance MHC-restricted antigen presentation and suppress M2 tumor-associated macrophages (M2 TAM), MDSCs and Tregs, but not M1 TAMs, DCs, and effector T cells. Agonist anti-CD40 provides co-stimulatory signal, increases antigen presentation, and stimulates CD4+ and CD8+ T cells. Complementary drug action of the MEKi/CD40 Ab combination exerts synergistic antitumor effects.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 76

Metadata

Authors
Baumann, D., Hägele, T., Mochayedi, J., Drebant, J., Vent, C., Blobner, S., Noll, J. H., Nickel, I., Schumacher, C., Boos, S. L., Daniel, A. S., Wendler, S., Volkmar, M., Strobel, O., & Offringa, R.
Affiliations
  • German Cancer Research Center (DE)
  • University Hospital Heidelberg (DE)
Corresponding author
Offringa, Rienk
Venue
Nature Communications
Published
2020-05-01
Volume
11
Issue
1
Pages
2176-2176
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3022874852
Cited by
76
References
73
Citations by year
2026: 10 · 2025: 8 · 2024: 13 · 2023: 13 · 2022: 15 · 2021: 10 · 2020: 7
FWCI
4.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
Funders
  • Deutsches Krebsforschungszentrum
  • K.H. Bauer foundation
  • Federal Ministry of Education and Research
  • K.H. Bauer foundation Federal Ministry of Education and Research
  • K.H. Bauer foundation The European Union
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
MEK inhibition, MAPK kinase, combination immunotherapy, tumor microenvironment, myeloid-derived suppressor cells, regulatory T cells, KRAS-mutant tumors, pancreatic ductal adenocarcinoma, immune checkpoint inhibitor resistance, cytostatic agents
MeSH terms
Adenocarcinoma, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Dendritic Cells, Drug Synergism, Humans, Macrophages, Male, Mice, Inbred C57BL, T-Lymphocytes, CD40 Antigens, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, Biomarkers, Pharmacological, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. https://app.cochat.ai/papers/10.1038/s41467-020-15979-2
The paper
Baumann, D., Hägele, T., Mochayedi, J., Drebant, J., Vent, C., Blobner, S., Noll, J. H., Nickel, I., Schumacher, C., Boos, S. L., Daniel, A. S., Wendler, S., Volkmar, M., Strobel, O., & Offringa, R. (2020). Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nature Communications. https://doi.org/10.1038/s41467-020-15979-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.